Log in to save to my catalogue

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5648545

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

About this item

Full title

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2016-11, Vol.375 (19), p.1845-1855

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Patients with surgically resected stage III melanoma are at high risk for recurrence. The 5-year survival rate with ipulimumab was 11 percentage points higher than that with placebo (65% vs. 54%), but there were substantial immune-related toxic effects.
Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (C...

Alternative Titles

Full title

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5648545

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5648545

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1611299

How to access this item